Head-to-head evidence
filgotinib vs tofacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: JAK · full Rheumatoid Arthritis pipeline
filgotinib · Jyseleca
Marketed by Gilead Sciences and partners
NCT02873936 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).
Next expected readout: April 2029 · NCT06687551 (registry estimate)
tofacitinib · Xeljanz
Marketed by Pfizer
NCT01262118 · Phase 1 · completed
This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.
Next expected readout: January 2027 · NCT06945666 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · tofacitinib's landscape